Cargando…
1569. Incidence, Risk Factors, and Impact of Antiviral Prophylaxis Duration on Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative [D+R−] Orthotopic Heart Transplant Recipients (OHTR)
BACKGROUND: CMV disease is a major cause of morbidity and mortality in OHTR, especially among D+R− patients. Clinical trials of longer antiviral prophylaxis have shown reduced CMV disease incidence in kidney and lung transplant recipients but have not been done in OHTR. We aimed to characterize risk...
Autores principales: | Carcoana, Allison Dumitriu, Imlay, Hannah, Fisher, Cynthia, Wong, Beatrice, Rakita, Robert, Limaye, Ajit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253048/ http://dx.doi.org/10.1093/ofid/ofy210.1397 |
Ejemplares similares
-
Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients
por: McBride, Jacqueline M, et al.
Publicado: (2019) -
LB21. Preemptive Therapy (PET) vs. Prophylaxis for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Donor Seropositive/Recipient Seronegative (D+R−) Liver Transplant Recipients (LTR): A NIH-Sponsored, Randomized, Controlled, Multicenter Trial
por: Singh, Nina, et al.
Publicado: (2018) -
Donor CMV Reactivation as a Novel Risk Factor for CMV Replication in Seropositive Liver Transplant Recipients
por: Limaye, Ajit P., et al.
Publicado: (2020) -
A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020) -
A Systematic Review and Meta-analysis of Optimized CMV Preemptive Therapy and Antiviral Prophylaxis for CMV Disease Prevention in CMV High-Risk (D+R-) Kidney Transplant Recipients
por: Kumar, Lakshin, et al.
Publicado: (2023)